SEEK has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approximately 90%) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.
The development of an effective vaccine against HIV has been extremely difficult because the HIV virus constantly mutates. However, SEEK’s HIV-v vaccine targets only the conserved regions in the internal proteins of the HIV virus which remain constant across all HIV strains. It is the first vaccine to generate both strong T-cell and antibody responses to eliminate HIV-infected cells and thus neutralize the HIV virus. These features mean that the vaccine, while initially tested in an early stage of the disease as a therapeutic, could also be effective as a prophylactic, pending confirmation in a future trial.
Release Date: July 18, 2011
Filed Under: Drug Discovery